MS-8209, a new amphotericin B derivative, provides enhanced efficacy in delaying hamster scrapie.
To test the efficacy of a new amphotericin B derivative, MS-8209, in delaying scrapie, hamsters were infected intracerebrally with the 263K scrapie agent and treated with MS-8209 either early in the course of the disease or continuously. The results show that (i) all treatments lengthened the incubation period of hamster scrapie, (ii) continuous treatment with MS-8209 doubled the length of the incubation period compared with that observed in infected, untreated animals, and (iii) all treatments delayed the accumulation of a proteinase-resistant prion protein and glial fibrillary acidic protein in the brain. These findings suggest that MS-8209 is a powerful tool for investigating the pathogenesis of transmissible subacute spongiform encephalopathies.
Adjou
K T
KT
Départment de la Recherche Médicale, Commissariat à l'Energie Atomique, Fontenay aux Roses, Paris, France.
Demaimay
R
R
Lasmezas
C
C
Deslys
J P
JP
Seman
M
M
Dormont
D
D
D000666:Amphotericin B / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000818:Animals; D002490:Central Nervous System / Q000187:drug effects / Q000378:metabolism; D006224:Cricetinae; D005260:Female; D005904:Glial Fibrillary Acidic Protein / Q000096:biosynthesis; D008647:Mesocricetus; D018620:PrPSc Proteins / Q000096:biosynthesis; D012608:Scrapie / Q000188:drug therapy* / Q000378:metabolism
D005904:Glial Fibrillary Acidic Protein; D018620:PrPSc Proteins; C074660:MS 8209; D000666:Amphotericin B